Table 1.

CGVHD characteristics of patients in a immunohistochemistry study

Patient	Age	Months post HSCT	Months post cGVHD diagnosis	Systemic immune suppression at the time of evaluationa	NIH global cGVHD severity scoreb	Number of organ systems affected	Oral cGVHDc,d	Skind,e	PBMC Tregf	Total % BSAg erythema	Total % BSAg sclerosis
1	53	13	7	GC, TL, MMF, ECP	Severe	4	Severe	Lichenoid	FACS	30	0
2	50	9	2	GC, CSA	Moderate	4	Severe	Lichenoid	FACS	21	0
3	47	6	2	GC	Moderate	3	Severe	Lichenoid	FACS	5	0
4	22	9	3	GC, TL, MMF	Moderate	4	Severe	(Lichenoid)	FACS	26	0
5	57	46	33	GC, TL, MMF, ECP	Severe	5	Severe	(Sclerotic)	FACS	0	51
6	40	55	24	GC, MMF, SL, R	Severe	4	Severe	Sclerotic		8	49
7	56	28	10	GC, TL, MMF	Moderate	4	Severe	Lichenoid		18	0
8	51	64	61	GC, CSA, MMF	Severe	6	Severe	(Lichenoid)		3	0
9	45	6	3	CSA	Moderate	6	(Severe)	Lichenoid	FACS	1	0
10	58	5	3	Noneh	Moderate	2	Severe	Lichenoid	FACS	0	0
11	41	147	135	Noneh	Severe	5	Mild	Sclerotic		0	30
12	44	33	28	CSA, MMF	Moderate	3	Mild	None		0	0
13	39	58	56	GC, TL, HCQ	Severe	5	Mild	Sclerotic	FACS	5	70
14	44	205	198	MMF, CSA, ECP	Severe	7	Mild	Sclerotic		0	30
15	42	100	92	GC	Moderate	3	Mild	(None)		0	0
16	59	22	13	GC, TL	Severe	4	Mild	Sclerotic	FACS	0	20
17	36	41	35	MMF	Moderate	5	Mild	(None)		0	1
18	36	29	19	Noneh	Moderate	4	Mild	(None)		0	0
19	53	159	147	GC, CSA	Severe	3	Mild	(None)		0	0
20	55	5	3	GC, CSA	Moderate	6	Mild	Lichenoid	FACS	41	0
21	39	55	43	TL, MMF, ECP	Severe	6	Mild	Sclerotic		1	45
22	52	12	8	CSA	Moderate	6	Mild	Lichenoid		6	0
23	58	29	23	Noneh	Severe	3	Mild	(None)		0	0
24	45	27	20	GC	Severe	5	Mild	Sclerotic	FACS	2	64
25	60	43	25	GC, TL, MMF	Moderate	6	Mild	(Sclerotic)		0	5
26	56	27	0	Noneh	Moderate	3	None	Sclerotic		0	29
27	61	39	35	Noneh	Mild	2	None	None		0	0
28	39	59	34	TL, MMF	Severe	6	None	(None)		0	0
29	41	12	0	GC, MMF, CSA	Mild	2	None	None		0	0
30	49	28	15	Noneh	Moderate	3	None	None		0	0
31	40	22	16	GC, CSA	Severe	6	None	Lichenoid		7	0
32	62	11	6	Noneh	Moderate	5	(None)	Lichenoid	FACS	10	0
33	58	3	6	MMF	Moderate	4	(Mild)	Lichenoid	FACS	5	0
34	58	53	49	GC, MMF, ECP	Severe	2	(Mild)	Sclerotic	FACS	0	78
35	51	22	15	TL, GC	Severe	3	(None)	Sclerotic	FACS	0	62
36	42	48	44	TL, Imatinib	Severe	5	(Mild)	(Sclerotic)	FACS	1	81
37	59	24	9	ECP, GC	Severe	5	(None)	(Sclerotic)	FACS	2	74
38	34	13	9	TL, GC, Imatinib	Severe	7	(Mild)	(Sclerotic)	FACS	0	62
39	36	40	6	TL, MMF, ECP	Severe	5	(Mild)	(Sclerotic)	FACS	1	68
40	24	41	21	TL, Imatinib	Severe	4	(None)	(Sclerotic)	FACS	5	62

Abbreviations: BSA, body surface area; cGVHD, chronic graft versus host disease; CSA, cyclosporine A; ECP, extracorporeal photopheresis; GC, prednisone or other glucocorticoid; HSCT, hematopoietic stem cell transplantation; MMF, mycophenolate mofetil; PBMC, peripheral blood mononuclear cell; R, rituximab; SL, sirolimus; TL, tacrolimus.

^aCurrent systemic immunosuppression regimen.

^bNIH score: Mild—only one or two organs (excluding lungs) with a maximum NIH score of 1 in all organs; Moderate—at least one organ with a score of 2 or lungs with a score of 1, or three or more organs with a max score of 1; Severe—lung score of 2 or any other organ system scoring 3.

^cOral cGVHD was evaluated and graded by an oral medicine specialist using the following severity scoring system: normal mucosa, none; hyperkeratotic, lichenoid changes and/or erythema, mild; lichenoid changes and presence of ulcerations, severe.

^dAll patients were evaluated clinically and biopsies were reviewed for GVHD pathology, but biopsies that were not further examined by IHC for FoxP3 are listed in parentheses.

^eCutaneous cGVHD was evaluated and graded by an experienced dermatologist as having no evidence of cutaneous cGVHD (None), involving primarily lichen planus-like epidermal changes (Lichenoid) or involving primarily dermal or fascial sclerotic changes (Sclerotic).

^fPatients with severe lichenoid oral or cutaneous cGVHD (or both) whose cryopreserved PBMC were examined for FoxP3⁺ Treg subpopulations are noted as FACS.

^gThe percentages of the BSA affected by cutaneous cGVHD are noted.

^hThree of the eight not currently on therapy had received no prior systemic treatment, but only patient 26 was newly diagnosed with cGVHD.